Dutasteride 0.5mg + Minoxidil 5mg Combination Vegetarian Capsules — Full-Potency Dual-Action Hair Loss Treatment
This is our flagship dual-action hair loss capsule. So it combines standard-dose dutasteride 0.5mg with full-strength oral minoxidil 5mg. In fact, this pairs the two most evidence-supported oral hair loss medicines in one daily capsule. Furthermore, it targets pattern hair loss through two different mechanisms at once. Additionally, the vegetarian HPMC capsule format suits vegetarian, vegan, halal, and kosher patients. However, both components are off-label for hair loss. Dutasteride is MHRA-licensed only for BPH. Also, oral minoxidil is licensed only for severe hypertension. Above all, this treatment needs proper clinical review, informed consent, and cardiovascular assessment. Available at Courier Pharmacy after full assessment.
At Courier Pharmacy, we believe in treatment that fits the person, but only where it’s honest, safe, and consented to.
This page covers what our combination capsule is, how both mechanisms work together, the cardiovascular safety framework for 5mg oral minoxidil, the female use requirements, and the practical points that matter.
The off-label prescribing gateway — please read first
Before going further, we want to be straight about how supply works at Courier Pharmacy:
What off-label prescribing means
Both components are off-label for hair loss. So informed consent is essential.
- Dutasteride is MHRA-licensed for BPH at 0.5mg only
- Oral minoxidil is MHRA-licensed for severe hypertension only
- Standard hypertension doses are 10-40mg (much higher than hair loss doses)
- Both uses at these hair loss doses are off-label
- Off-label doesn’t mean unsafe or experimental
- Growing evidence supports both approaches
- Widely used off-label in UK private dermatology
- Off-label status means informed consent is essential
The cardiovascular assessment
5mg oral minoxidil needs cardiovascular review. So we check:
- Any history of hypertension
- Any history of heart conditions
- Any history of arrhythmias
- Any history of heart failure
- Family history of cardiovascular disease
- Current cardiovascular medications
- Any peripheral edema history
- Any pericardial disease history
Female use requires specific criteria
Both components need female-specific review:
- Postmenopausal women are the preferred candidate group
- Premenopausal women can use it with strict birth control
- Birth control must continue for 6 months after stopping
- Reliable methods preferred (IUD, implant)
- Written informed consent about birth defect risk essential
- Hypertrichosis (unwanted body hair) risk higher in women
- Consider lower minoxidil doses initially for women
What the assessment covers
Our review addresses critical areas:
- Diagnosis confirmation (photographs usually needed)
- Past hair loss treatments tried
- Understanding of off-label status for both components
- Full cardiovascular history and current status
- Baseline blood pressure and heart rate
- Menopausal status (for female patients)
- Birth control status and reliability
- Any relevant medical history
- Family history of prostate cancer (for men)
- Family history of heart disease
- Current medications review
- Any soya or peanut allergy
- Baseline sexual function check
- Mental health status check
- Future fertility planning
- Blood donation status
- Whether starting lower would suit better
Who this treatment isn’t suitable for
Absolute contraindications include:
- Pregnancy — birth defect risk causing severe harm
- Women planning imminent pregnancy
- Premenopausal women without reliable birth control
- Breastfeeding mothers
- Children and adolescents under 18
- Adults with pheochromocytoma
- Adults with active heart failure
- Adults with severe hypertension
- Adults with recent myocardial infarction
- Adults with pericardial effusion
- Adults with hypersensitivity to dutasteride, 5-ARIs, or minoxidil
- Adults with severe liver problems
- Adults with severe kidney problems
- Adults with active mental health crisis
Signposting when this combination isn’t right
If our review shows this combination isn’t right, we signpost well:
- Cardiovascular concerns — start with dutasteride monotherapy
- Early hair loss — start with topical minoxidil first
- Female patients wanting gentler dose — 0.15mg or 0.25mg dutasteride
- Premenopausal women without reliable birth control — different pathway
- Complex cases — dermatology referral
- Severe hair loss — surgical options may work alongside
Five key takeaways
- This is our flagship dual-action hair loss capsule. So it combines dutasteride 0.5mg with oral minoxidil 5mg. Furthermore, it targets pattern hair loss through two different mechanisms at once. In particular, this pairs the two most evidence-supported oral hair loss medicines
- BOTH components are off-label for hair loss. So dutasteride is MHRA-licensed for BPH only. Also, oral minoxidil is licensed only for severe hypertension. However, growing evidence supports both uses at these doses
- 5mg oral minoxidil needs cardiovascular assessment. So blood pressure, heart rate, and cardiovascular history all matter. Furthermore, some patients need to titrate up gradually. Not for patients with severe hypertension, heart failure, or pheochromocytoma
- Female patients need dutasteride safety framework. Postmenopausal women preferred; premenopausal women need reliable birth control throughout treatment and 6 months after. Also, hypertrichosis risk higher in women
- Vegetarian HPMC capsules suit vegetarian, vegan, halal, kosher patients. Also suits soya or peanut allergy patients. Not for pregnancy, breastfeeding, children, active heart failure, severe hypertension, or component hypersensitivity
Why choose Courier Pharmacy for combination therapy
At Courier Pharmacy, our approach starts with a simple idea. So treatment should fit the person, not force the person to fit the system.
Dr Ada Jex-Cori
Our service is shaped by the philosophy of Dr Ada Jex-Cori, our brand pharmacist.
Dr Ada represents the spirit of the pharmacy. So she is evidence-led, community-rooted, and willing to challenge one-size-fits-all medicine. Furthermore, she is named in honour of three pioneering women in science.
In our fictional world of Etherwell, Dr Ada fights against standardised approaches. In the real world, she represents what we stand for. Above all, her view is straightforward. You are not broken. The system is.
Evidence-based combination therapy
Not all combinations have the same evidence base. Courier Pharmacy is different. So we recognise that:
- Combination therapy has genuine evidence support
- 2025 UK cohort study of 621 patients confirmed benefits
- Panchaprateep 2020 showed 100% improvement at 5mg minoxidil
- Dutasteride 0.5mg has extensive off-label evidence
- Combining evidence-supported medicines is rational
- Full-potency dose combination for maximum effect
Honest framing about efficacy
The evidence picture:
- Combination typically works better than monotherapy
- Response better in earlier stages of hair loss
- Advanced hair loss may see less dramatic response
- Individual response varies significantly
- Not everyone responds equally to both components
- Some patients need dose adjustment over time
Honest framing about limits
What we don’t offer:
- We don’t offer this to pregnant women
- We don’t offer to premenopausal women without birth control
- We don’t offer to patients with severe cardiovascular disease
- We don’t offer without full assessment
- We don’t offer surgical hair loss options
- For any of these needs, appropriate services fit better
Hair loss and the bigger picture
Pattern hair loss rarely sits in isolation. So our prescriber can discuss:
- Full hair loss review
- Underlying medical factors
- Cardiovascular health optimisation
- For women: hormonal factors and menopausal status
- Mental wellbeing impact of hair loss
- Combination treatment strategies
- Long-term management planning
- When to consider surgical options alongside
Prescriber support throughout treatment
Our team is here to discuss:
- Whether this combination fits your specific case
- Whether starting lower would suit better
- Managing any cardiovascular effects
- Managing sexual side effects if they occur
- Managing hypertrichosis if concerning
- Tracking progress meaningfully
- Adjusting approach based on response
- Long-term treatment planning
Trust earned, not claimed
We are GPhC-regulated. So our content is grounded in evidence. In particular, the Panchaprateep 2020 open-label study of 5mg oral minoxidil directly informs our positioning. Furthermore, we reference the Sanabria 2023 cardiovascular safety study, the 2025 systematic review, extensive dutasteride evidence, and the 2025 UK cohort study of combination approaches.
If this combination isn’t the right answer for your case, we’ll tell you honestly.
More than a prescription: our community
Healthcare shouldn’t only happen when you’re paying for it.
Every fortnight we run free drop-in talks and clinics at Insomnia, Derby, from 10am to 12pm. So we show up, even when it’s free.
Bring a question, bring a friend, bring a stack of bewildering letters from another clinic. We’ll sit with you.
We cover weight management, GLP-1 therapy, MCAS, menopause, women’s health including female hair loss, men’s health, chronic pain, digestive health, allergies, asthma, sleep, migraine, skincare, acne, alcohol use disorder support, and whatever else people bring through the door. No appointment. No cost. No pressure. Just real support and treatment that fits.
Active ingredients and capsule composition
Each capsule contains
- Dutasteride 0.5mg (as active ingredient)
- Minoxidil 5mg (as active ingredient)
- Microcrystalline cellulose (as filler)
- Standard capsule excipients supporting stability
Capsule shell composition
- Vegetarian HPMC capsules (Hydroxypropyl methylcellulose)
- Suitable for vegetarian and vegan patients
- Free from gelatin
- Free from soybean oil (unlike branded Avodart)
- Free from common allergens
- Halal and kosher suitable
Why these doses specifically
The dose combination has specific rationale:
- Dutasteride 0.5mg: standard evidence-supported hair loss dose
- Reduces DHT by 90-95% at this dose
- Same dose as branded Avodart
- Oral minoxidil 5mg: upper studied dose for hair loss
- Panchaprateep 2020 showed 100% improvement at 5mg
- 43% showed excellent improvement (71-100% increase)
- Well below hypertension doses (10-40mg)
- Favourable cardiovascular safety at this dose
What this combination is for
This combination capsule provides full-potency dual-action treatment. So the medicine addresses pattern hair loss through both DHT blockade AND blood flow enhancement.
Furthermore, this dual mechanism often works better than monotherapy. Also, one daily capsule replaces two separate treatments.
Understanding pattern hair loss
The clinical picture:
- Progressive hair loss driven by genetic hormonal sensitivity
- DHT causes follicle miniaturisation
- Reduced scalp blood flow limits follicle recovery
- Inflammation plays a role
- Multiple mechanisms drive progression
- Single-agent treatments address only part of the problem
- Combination approaches often work better
Why dual-action makes sense
The rationale for combination:
- Dutasteride blocks DHT production
- Oral minoxidil promotes hair growth
- Different mechanisms target different aspects
- Evidence supports combination approaches
- 2025 UK cohort study of 621 patients showed combination benefits
- Full-potency dose combination for maximum effect
Who might benefit most
This combination may suit:
- Adults with advanced pattern hair loss
- Adults who haven't responded to monotherapy
- Men wanting maximum oral treatment effect
- Postmenopausal women with severe hair loss
- Adults wanting once-daily simplicity
- Adults who have tolerated lower doses well
- Adults with realistic expectations
Who might suit lower-dose options
Some patients suit gentler approaches first:
- New patients starting oral treatment
- Patients with any cardiovascular concerns
- Elderly patients
- Women wanting to start gently
- Patients preferring titration approach
- Patients with mild-to-moderate hair loss
How to take this combination
Standard dosing
The straightforward routine:
- Take one capsule once daily
- Swallow the capsule whole with water
- Don't chew, crush, or open the capsule
- Take at about the same time each day
- With or without food
- Continue daily to maintain benefits
- Any missed dose: take when remembered same day
Titration approach if appropriate
Some patients start with lower doses first:
- Alternative products in our range support this approach
- Start with dutasteride 0.5mg + minoxidil 2.5mg
- Increase gradually over 3-6 months
- Move to this 5mg product when tolerating lower doses well
- Prescriber guides your specific pathway
Practical tips
- Set up a daily routine
- Set a phone reminder if needed
- Take before-treatment photographs
- Track progress at 3, 6, and 12 months
- Monitor blood pressure regularly
- Report any concerning symptoms promptly
- Attend regular reviews with our prescriber
- For women: maintain reliable birth control without gaps
Monitoring during treatment
Regular monitoring supports safe treatment:
- Blood pressure check monthly for first 3 months
- Then every 3-6 months if stable
- Watch for peripheral edema (ankle swelling)
- Report any palpitations or racing heart
- Report any breathlessness
- Track hair progress with photographs
- Report any concerning symptoms
What to combine with
Full hair loss treatment may need extra elements:
- Regular scalp check
- Healthy diet and good nutrition
- Iron and vitamin D optimisation
- Stress management
- Sleep hygiene
What to avoid
- Sharing medication with others
- Blood donation during or within 6 months of treatment
- Stopping suddenly (especially minoxidil component)
- Doubling doses if missed
- Combining with other 5-ARIs or vasodilators
- For premenopausal women: birth control gaps
Storage
- Store below 25°C
- In original packaging
- Protect from light and moisture
- Keep out of sight and reach of children
- Keep away from pregnant women
- Use by expiry date
Warnings and precautions
Absolute contraindications
- Pregnancy (dutasteride birth defect risk)
- Women planning imminent pregnancy
- Premenopausal women without reliable birth control
- Breastfeeding mothers
- Children and adolescents under 18
- Pheochromocytoma
- Active heart failure
- Severe hypertension
- Recent myocardial infarction
- Pericardial effusion or pericarditis
- Hypersensitivity to dutasteride, 5-ARIs, or minoxidil
- Severe liver problems
- Severe kidney problems
- Active mental health crisis
The cardiovascular safety consideration
Critical safety points for the minoxidil component:
- Minoxidil is a vasodilator
- Can cause reflex tachycardia (racing heart)
- Can cause fluid retention
- Can cause peripheral edema (ankle swelling)
- Rarely: pericardial effusion
- Regular blood pressure monitoring recommended
- Report any cardiovascular symptoms immediately
- Not for use with severe cardiovascular disease
The dutasteride birth defect risk
Critical safety point for the dutasteride component:
- Dutasteride can cause birth defects if a pregnant woman is exposed
- Particular risk to male fetuses
- Absorbed through skin from broken capsules
- Pregnant women should NEVER touch broken capsules
- Birth control essential throughout treatment
- Birth control continues 6 months after stopping
- Store safely away from pregnant women
The hypertrichosis consideration
Unwanted body hair growth is common:
- Very common at 5mg oral minoxidil (93% of patients)
- Most common on face, arms, and back
- Usually gradual increase over first 3-6 months
- Higher impact for women
- Can be managed with hair removal methods
- Reversible on stopping treatment
- Consider lower minoxidil doses if concerning
The sexual side effects consideration
Dutasteride component effects:
- Sexual side effects possible with dutasteride
- Men: possible reduced libido, ejaculatory changes, erectile issues
- Women: possible reduced libido, hormonal shifts
- Effects usually reversible on stopping
- Long half-life means effects last weeks after stopping
- Report any sexual side effects immediately
The mood consideration
- Depression reported with 5-ARI use
- Anxiety reported
- Suicidal ideation reported (rare but serious)
- Not for use during active mental health crisis
- Report mood changes promptly
- Any suicidal thoughts: contact GP, NHS 111, Samaritans (116 123), or 999
The PSA consideration (for men)
- Dutasteride reduces PSA levels by about 50%
- Always tell any healthcare provider
- Baseline PSA before treatment may be advised
The blood donation restriction
- Cannot donate blood while taking dutasteride
- Cannot donate for 6 months after last dose
- Applies to any dutasteride use
- Tell NHS Blood and Transplant
Use with care if you
- Have mild-to-moderate hypertension
- Have moderate liver problems
- Have moderate kidney problems
- Have any cardiovascular history
- Take medications interacting with CYP3A4
- Have any history of mood difficulties
- Are elderly
- Have other chronic conditions
- Are approaching family planning
When to seek urgent medical help
- Signs of severe allergic reaction
- Racing heart, chest pain, or palpitations
- Severe breathlessness
- Significant ankle swelling
- Any suicidal thoughts
- Severe or lasting mood changes
- Signs of hepatitis (jaundice, dark urine, abdominal pain)
- Any breast lump
- For women: any suspicion of pregnancy
- Any concerning symptoms
Side effects
Combined side effect profile of both components.
Very common side effects (may affect more than 1 in 10 people)
- Hypertrichosis (unwanted body hair) — 93% at 5mg minoxidil
- Reduced libido
Common side effects (may affect up to 1 in 10 people)
- Peripheral edema (ankle swelling) — about 10% at 5mg
- Erectile dysfunction (in men)
- Ejaculatory disorders (in men)
- Breast tenderness
- Dizziness
- Headache
- Palpitations (mild)
- Fluid retention
Uncommon side effects
- Marked ankle or leg swelling
- Weight gain from fluid retention
- Allergic reactions
- Depression
- Menstrual changes (in premenopausal women)
- Postural hypotension (dizziness on standing)
Rare side effects
- Severe allergic reactions
- Testicular pain (in men)
- Marked tachycardia
- Pericardial effusion (very rare)
Very rare/frequency unknown
- Anxiety
- Suicidal ideation
- Male breast cancer (very rare)
- Post-5-ARI syndrome
- Severe cardiovascular events
Yellow Card reporting
If you experience any side effects, talk to your prescriber or contact us. You can also report side effects directly via the MHRA Yellow Card scheme at https://yellowcard.mhra.gov.uk. By reporting side effects, you help provide more information on the safety of medicines.
Frequently asked questions
Why combine dutasteride and minoxidil in one capsule?
The rationale:
- Different mechanisms target different aspects of hair loss
- Dutasteride blocks DHT (the cause)
- Minoxidil promotes hair growth (the treatment)
- Combined effect greater than either alone
- One daily capsule simpler than two separate medications
- Evidence supports combination approaches
Is 5mg oral minoxidil safe?
At this dose, evidence supports safety with appropriate assessment:
- Panchaprateep 2020 study showed favourable safety at 5mg
- Sanabria 2023 Holter/ABPM study showed no cardiovascular issues
- Multi-center safety study of 1,404 patients supports use
- Well below standard hypertension doses (10-40mg)
- Requires cardiovascular assessment before starting
- Regular blood pressure monitoring recommended
Should I start at 5mg or titrate up?
Individual pathway depends on your circumstances:
- Adults with good cardiovascular health may start at 5mg
- Adults with any cardiovascular concerns should titrate up
- Titration: 1.25mg ? 2.5mg ? 5mg over 3-6 months
- Alternative products in our range support lower starting doses
- Prescriber guides your specific pathway
Will I grow hair on my face and body?
Hypertrichosis is very common at 5mg oral minoxidil:
- 93% of patients experience some hypertrichosis
- Most common on face, arms, and back
- Gradual increase over first 3-6 months
- Can be managed with hair removal methods
- Reversible on stopping treatment
- Consider lower minoxidil doses if concerning
Do I need blood pressure monitoring?
Yes, monitoring supports safe treatment:
- Baseline blood pressure needed before starting
- Monthly checks for first 3 months
- Then every 3-6 months if stable
- Home blood pressure monitor useful
- Report any significant changes
- Also watch for ankle swelling
Can women take this combination?
Yes, with important criteria:
- Postmenopausal women are preferred candidates
- Premenopausal women need reliable birth control
- Birth control continues 6 months after stopping
- Hypertrichosis risk higher in women
- Consider lower doses (0.15mg or 0.25mg dutasteride) first
- Individual assessment guides suitability
Is this doubly off-label?
Yes — both components off-label for hair loss:
- Dutasteride licensed for BPH at 0.5mg only
- Oral minoxidil licensed for severe hypertension only
- Both uses for hair loss are off-label
- However, off-label prescribing is permitted
- Growing evidence supports both uses
- Informed consent essential
How long until I see results?
Realistic timeline:
- First 4-8 weeks: initial shedding phase possible
- Months 3-6: visible improvement typically emerges
- Months 6-12: significant improvement in many patients
- Beyond 12 months: continued benefit
- Full response may take 12-24 months
Can I stop taking this?
Yes, but consider:
- Discuss stopping with prescriber first
- Sudden stopping is generally safe
- Benefits reverse gradually over months
- Hair may return to pre-treatment state
- Hypertrichosis reverses on stopping
- Blood pressure effects reverse quickly
Is this suitable for vegans?
Yes:
- HPMC capsules are plant-based
- No animal components
- Suitable for vegetarian and vegan patients
- Also suitable for halal and kosher observance
How do I order?
Complete the hair loss consultation on courierpharmacy.co.uk. Our prescriber reviews your specific case including cardiovascular status. So they confirm whether this combination is appropriate. Furthermore, if a different combination or lower doses would suit better, we'll suggest that.
Disclaimer: This page is for information only and isn't a substitute for personal medical advice. This combination contains dutasteride and minoxidil — both prescription-only medicines (POM). Dutasteride is MHRA-licensed for BPH at 0.5mg only.
Oral minoxidil is MHRA-licensed for severe hypertension only. Use of this combination for pattern hair loss is DOUBLY OFF-LABEL — permitted under GMC and GPhC guidance when clinically justified with informed consent.
Dutasteride can cause severe congenital defects and is ABSOLUTELY CONTRAINDICATED during pregnancy, in women planning imminent pregnancy, in premenopausal women without reliable contraception, and in breastfeeding mothers.
Pregnant women must NEVER handle broken or leaking capsules. For female patients: reliable contraception is essential throughout treatment and for 6 months after stopping (due to dutasteride long half-life of approximately 5 weeks).
Oral minoxidil at 5mg is ABSOLUTELY CONTRAINDICATED in patients with pheochromocytoma, active heart failure, severe hypertension, recent myocardial infarction, and pericardial effusion. Requires baseline cardiovascular assessment and ongoing blood pressure monitoring.
Also contraindicated in children and adolescents, adults with hypersensitivity to 5-ARIs or minoxidil, severe hepatic impairment, severe renal impairment, and acute mental health crisis. Hypertrichosis (unwanted body hair growth) is very common at 5mg (93% of patients). Peripheral edema common (10%). Blood donation ABSOLUTELY PROHIBITED during treatment and for 6 months after last dose. Sexual side effects may persist longer than expected due to dutasteride long half-life.
Mood changes, depression, and suicidal ideation reported — any suicidal thoughts should trigger immediate contact with GP, NHS 111, Samaritans (116 123), or emergency services (999). For men: PSA levels reduced by approximately 50%. Signs of severe allergic reaction, chest pain, palpitations, or significant ankle swelling require immediate medical attention (999). Any suspicion of pregnancy in a female patient requires immediate treatment cessation and medical assessment.
How this content was created
Written by the Courier Pharmacy editorial team and reviewed by a GPhC-registered prescribing pharmacist.
The content is grounded in the licensed dutasteride and minoxidil Summary of Product Characteristics, MHRA guidance on off-label prescribing, GMC/GPhC guidance on responsible off-label supply, Panchaprateep 2020 open-label study of 5mg oral minoxidil, Sanabria 2023 cardiovascular safety study with 24-hour Holter and ABPM monitoring, 2025 systematic review of low-dose oral minoxidil adverse events, multi-center safety study of 1,404 patients on low-dose oral minoxidil, extensive dutasteride evidence base, and the 2025 UK cohort study of 621 patients on combination approaches.
References
- Panchaprateep, R. and Lueangarun, S. (2020) 'Efficacy and safety of oral minoxidil 5 mg once daily in the treatment of male patients with androgenetic alopecia: an open-label and global photographic assessment', Dermatology and Therapy (Heidelberg), 10(6), pp. 1345–1357. Available at: https://doi.org/10.1007/s13555-020-00448-x (Accessed: 14 June 2026).
- Sanabria, B.D., Palmegiani, E., Seron, A.F., Perdomo, Y.C., Miot, H.A. and Müller Ramos, P. (2023) 'Prospective cardiovascular evaluation with 24-hour Holter and 24-hour ambulatory blood pressure monitoring in men using 5-mg oral minoxidil for androgenetic alopecia', Journal of the American Academy of Dermatology, 88(2), pp. 436–437. Available at: https://doi.org/10.1016/j.jaad.2022.05.026 (Accessed: 14 June 2026).
- Cabrera-Colmenero, D., Bataille-Barbero, A. and Sánchez-Cuenca, I. (2025) 'Characterization and management of adverse events of low-dose oral minoxidil treatment for alopecia: a narrative review', Journal of Clinical Medicine, 14(6), 1805. Available at: https://doi.org/10.3390/jcm14061805 (Accessed: 14 June 2026).
- Olsen, E.A., Hordinsky, M., Whiting, D., Stough, D., Hobbs, S., Ellis, M.L., Wilson, T. and Rittmaster, R.S. (2006) 'The importance of dual 5?-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride', Journal of the American Academy of Dermatology, 55(6), pp. 1014–1023. Available at: https://doi.org/10.1016/j.jaad.2006.05.007 (Accessed: 14 June 2026).
- Eun, H.C., Kwon, O.S., Yeon, J.H., Shin, H.S., Kim, B.Y., Ro, B.I., Cho, H.K., Sim, W.Y., Lew, B.L., Lee, W.S., Park, H.Y., Hong, S.P. and Ji, J.H. (2010) 'Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study', Journal of the American Academy of Dermatology, 63(2), pp. 252–258. Available at: https://doi.org/10.1016/j.jaad.2009.09.018 (Accessed: 14 June 2026).
- Boersma, I.H., Oranje, A.P., Grimalt, R., Iorizzo, M., Piraccini, B.M. and Verdonschot, E.H. (2014) 'The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia', Indian Journal of Dermatology, Venereology and Leprology, 80(6), pp. 521–525. Available at: https://doi.org/10.4103/0378-6323.144162 (Accessed: 14 June 2026).
- Gupta, A.K., Bamimore, M.A., Williams, G. and Talukder, M. (2025) 'Comparative efficacy of minoxidil and 5-alpha reductase inhibitors monotherapy for male pattern hair loss: network meta-analysis study of current empirical evidence', Journal of Cosmetic Dermatology, 24(7), e70320. Available at: https://doi.org/10.1111/jocd.70320 (Accessed: 14 June 2026).
- Johnson, H., Rae, D., Barrett, Z., Hendricks, K., García Aguilar, H., Bevan, S. and Huang, D. (2025) Efficacy and safety of oral dutasteride 0.5 mg combined with oral minoxidil 2.5 mg for male androgenetic alopecia: a retrospective cohort study [Preprint]. Research Square. Available at: https://www.researchsquare.com/article/rs-10446116/v1 (Accessed: 14 June 2026).
- Courier Pharmacy (2026) Dutasteride Hair Loss UK: Patient Guide (2026). Courier Pharmacy. Available at: https://courierpharmacy.co.uk/dutasteride-hair-loss-uk-patient-guide-2026/ (Accessed: 30 July 2026).
- Courier Pharmacy (2026) Minoxidil and Hair Growth: From Discovery to Modern Mechanisms. Courier Pharmacy. Available at: https://courierpharmacy.co.uk/minoxidil-and-hair-growth-from-discovery-to-modern-mechansims/ (Accessed: 30 July 2026).
- Courier Pharmacy (2026) Dutasteride and Minoxidil: A Powerful Combination for Hair Loss in the UK. Courier Pharmacy. Available at: https://courierpharmacy.co.uk/dutasteride-and-minoxidil-a-powerful-combination-for-hair-loss-in-the-uk/ (Accessed: 30 July 2026).
